Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi(®)) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells

The treatment of cystic fibrosis (CF) patients homozygous for the F508del mutation with Orkambi(®), a combination of a corrector (lumacaftor) and a potentiator (ivacaftor) of the mutated CFTR protein, resulted in some amelioration of the respiratory function. However, a great variability in the clin...

Full description

Saved in:
Bibliographic Details
Published in:Int J Mol Sci
Main Authors: Favia, Maria, Gallo, Crescenzio, Guerra, Lorenzo, De Venuto, Domenica, Diana, Anna, Polizzi, Angela Maria, Montemurro, Pasqualina, Mariggiò, Maria Addolorata, Leonetti, Giuseppina, Manca, Antonio, Casavola, Valeria, Conese, Massimo
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7177453/
https://ncbi.nlm.nih.gov/pubmed/32244302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21072398
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items